Great Lakes Advisors LLC Invests $2.85 Million in Kura Oncology, Inc. $KURA
Great Lakes Advisors LLC has invested $2.85 million in Kura Oncology, acquiring 259,857 shares. The company has a "Moderate Buy" consensus rating from analysts with a target price of $25.62, and its recent quarterly earnings exceeded expectations. CEO Troy Edward Wilson also significantly increased his holdings by purchasing 100,000 shares for $1.11 million.
Kura Oncology (KURA) Q2 2026 Earnings Call Transcript
Kura Oncology reported strong Q2 2026 results, with KOMZIFTI achieving majority market share in new patient starts for relapsed/refractory NPM1-mutant AML. The company highlighted significant increases in net product revenue, new patient starts, and total prescriptions, driven by KOMZIFTI's differentiated profile and strong commercial execution. Kura also advanced its darlifarnib program, showing promise as a broad combination platform in solid tumors, and confirmed its financial strategy to fund the ziftomenib AML program through key pivotal trial results in 2028.
Kura Oncology (NASDAQ: KURA) exec plans to sell 31,487 shares
Kura Oncology officer Teresa Bair plans to sell 31,487 shares of common stock, valued at approximately $388,234.71, through Morgan Stanley Smith Barney LLC on August 19, 2026. These shares were acquired upon the vesting of restricted stock units between January 26, 2024, and January 26, 2026. The sale is being disclosed via a Form 144 filing, adhering to SEC regulations for insider stock resales.
Kura Oncology (KURA) is a Great Momentum Stock: Should You Buy?
Kura Oncology (KURA) has been identified as a strong momentum stock, earning a Zacks Momentum Style Score of B and a Zacks Rank of #2 (Buy). The company shows promise due to significant short-term price appreciation (up 13.48% in the past week and 71.49% in the last year), outperforming its industry and the S&P 500. Additionally, positive earnings estimate revisions further support its potential for continued upward movement.
Troy Wilson Bought 12% More Shares In Kura Oncology
Kura Oncology's Chairman, Troy Wilson, recently purchased US$1.1 million worth of stock at US$11.12 per share, increasing his holding by 12%. This was the largest insider purchase in the last year for the company, indicating an optimistic outlook, especially since the purchase was made near the current share price of US$12.33. Insiders own 1.5% of Kura Oncology, suggesting a reasonable degree of alignment with shareholder interests despite the company currently making losses.
Kura Oncology (NASDAQ:KURA) Hits New 52-Week High Following Insider Buying Activity
Kura Oncology (NASDAQ:KURA) shares recently hit a new 52-week high after CEO Troy Edward Wilson significantly increased his stake by purchasing 100,000 shares for $1.1 million. The company reported better-than-expected quarterly earnings, though it remains unprofitable. Analysts maintain a "Moderate Buy" rating with an average price target significantly above the current trading price.
Kura Oncology stock rises on CEO insider purchase
Kura Oncology Inc. (NASDAQ:KURA) shares saw a 5.4% increase in after-hours trading following an insider purchase by CEO Troy Edward Wilson. Wilson acquired 100,000 shares for approximately $1.1 million, signaling confidence in the company's prospects. Insider buys are generally seen as a positive indicator by market participants.
Troy Edward Wilson Purchases 100,000 Shares of Kura Oncology (NASDAQ:KURA) Stock
Kura Oncology CEO Troy Edward Wilson recently purchased 100,000 shares of the company's stock for $1.112 million, significantly increasing his direct stake. Despite the company being unprofitable, it surpassed quarterly EPS and revenue estimates, and analysts maintain a "Moderate Buy" rating with a target price of $25.62. Several institutional investors also increased their holdings in Kura Oncology, highlighting continued interest in the biopharmaceutical company.
Kura Oncology (NASDAQ: KURA) CEO buys more in 100,000-share insider trade
Kura Oncology's President and CEO, Troy Edward Wilson, reported an insider purchase of 100,000 shares of common stock at a weighted average price of $11.12 per share on August 17, 2026. These shares were acquired through multiple trades, ranging from $10.87 to $11.31, and are held indirectly by the One Fish Two Fish Revocable Trust. Following this transaction, the trust's holdings in Kura Oncology increased to 379,194 shares.
Kura Oncology Inc (KURA) (Q2 2026) Earnings Call Highlights: KOM
Kura Oncology Inc. (KURA) reported strong Q2 2026 results with KOMZIFTI net product revenue of $9.1 million, exceeding expectations and capturing a majority share in the relapsed/refractory NPM1-mutant AML menin inhibitor market. The company also highlighted promising frontline AML data for ziftomenib and efficacy for darlifarnib in other cancers. Despite a net loss of $68.3 million due to increased commercial costs, Kura Oncology maintains a strong cash position and expects to fund its ziftomenib program through phase III results in 2028.
Q3 EPS Estimates for Kura Oncology Boosted by HC Wainwright
HC Wainwright has increased its Q3 2026 EPS estimate for Kura Oncology (NASDAQ:KURA) to a loss of $0.85 per share, an improvement from their previous estimate of a $0.92 loss. The company's recent quarterly results surpassed expectations, reporting a loss of $0.77 per share against a consensus of $0.88 and revenue of $20.87 million compared to an expected $20.16 million. Despite projected losses through FY2029, analyst sentiment for Kura Oncology remains largely positive, holding a "Moderate Buy" consensus rating and an average price target of $25.62.
Kura Oncology (KURA) investors report up to 9.7% beneficial ownership stakes
Montanova Capital, LLC, Averill Master Fund, Ltd., and Aaron Cowen have reported significant beneficial ownership stakes in Kura Oncology, Inc. Montanova Capital and Aaron Cowen each own 9.7% of the common stock, while Averill Master Fund holds 8.8%. The reported shares are directly owned by advisory clients of Montanova Capital, LLC, with Averill Master Fund being the only client that beneficially owns more than 5%.
Kura Oncology (NASDAQ:KURA) Stock Price Up 8% on Analyst Upgrade
Kura Oncology (NASDAQ:KURA) saw its stock price rise 8% following an analyst upgrade from Wedbush, which increased its price target to $38 from $36 while maintaining an "outperform" rating. The company's Q2 results surpassed expectations with a narrower loss and higher revenue, driven by a 57% sequential increase in KOMZIFTI® revenue. Despite mixed analyst sentiment and a recent insider stock sale, positive momentum in its drug sales and future revenue projections contribute to investor optimism.
A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $23 to $40
This article provides a quick overview of analyst ratings for Kura Oncology (KURA.US), noting a forecast price range of $23 to $40. It indicates that the company is currently receiving a 'Buy' rating from analysts, reflecting positive sentiment. The information is presented as a snapshot of current market expectations for Kura Oncology.
Kura Oncology, Inc. Stock 12‑Month Price Target Raised to $32, Implies 222% Upside
Analysts have raised the average 12-month price target for Kura Oncology, Inc. (KURA) stock from $31.17 to $32, with forecasts ranging from $15 to $76 per share. This new target suggests a potential upside of approximately 222% from its August 12 closing price. The consensus rating from 15 analysts remains a "Buy," with 14 recommending Buy and 1 recommending Hold.
Kura Oncology (NASDAQ:KURA) Price Target Raised to $38.00 at Wedbush
Wedbush has increased its price target for Kura Oncology (NASDAQ:KURA) to $38.00 from $36.00, maintaining an "outperform" rating, which suggests a significant upside of 282.29% from its current stock price. This comes after Kura Oncology reported better-than-expected quarterly results, with a narrower loss per share and higher revenue than consensus estimates. Despite positive product momentum and anticipated collaboration revenue, the company remains deeply unprofitable with a negative net margin of 411.19%, and major clinical results are not expected until 2028.
Wedbush Adjusts Price Target on Kura Oncology to $38 From $36, Keeps Outperform Rating
Wedbush has increased its price target for Kura Oncology (KURA) shares to $38 from $36, while maintaining an Outperform rating on the stock. This adjustment comes as the company continues its clinical development in precision medicine for cancer treatment. Kura Oncology is focused on small molecule product candidates targeting cancer signaling pathways.
Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue Estimates
Kura Oncology (KURA) reported a Q2 loss of $0.77 per share, beating the Zacks Consensus Estimate of a $0.89 loss, and revenues of $20.87 million, surpassing estimates by 23.61%. Despite underperforming the S&P 500 year-to-date, the stock holds a Zacks Rank #2 (Buy) due to favorable estimate revisions, suggesting potential market outperformance. The company's immediate price movement will depend on management's commentary during the earnings call.
Kura Oncology Q2 Earnings Call Highlights
Kura Oncology reported Q2 revenue of $9.1 million from KOMZIFTI, its treatment for relapsed or refractory NPM1-mutated AML, securing a majority of new patient starts in the menin inhibitor market. The company also shared promising clinical data for ziftomenib combinations and advanced its darlifarnib program for solid tumors. Kura ended the quarter with $519 million in cash and expects collaboration payments to fund its AML program through anticipated phase 3 results in 2028.
Earnings call transcript: Kura Oncology tops Q2 2026 estimates as launch gains
Kura Oncology reported strong Q2 2026 results, exceeding Wall Street expectations due to robust early sales of its new cancer drug KOMZIFTI. The company posted a smaller-than-expected loss and higher revenue, driven by KOMZIFTI capturing a majority share of new patient starts in the relapsed/refractory NPM1 mutant AML market. Kura maintains a positive outlook, with cash reserves expected to fund its AML program through key phase III data readouts in 2028.
Kura Oncology Reports Second Quarter 2026 Financial Results
Kura Oncology announced its second quarter 2026 financial results, highlighting strong commercial performance for its drug KOMZIFTI® (ziftomenib), which generated $9.1 million in net product revenue and achieved a majority share of new patient starts in its class. The company also provided updates on its clinical pipeline, including positive data for ziftomenib in AML and darlifarnib in solid tumors, and reaffirmed its financial position with $519.0 million in cash and anticipated collaboration payments. Kura Oncology projects several commercial and clinical catalysts over the next 12 to 18 months, aiming to expand ziftomenib's use across the AML treatment continuum and advance darlifarnib as a precision combination platform.
Kura Oncology Reports Second Quarter 2026 Financial Results
Kura Oncology announced its second-quarter 2026 financial results, highlighting strong commercial performance for its drug KOMZIFTI® (ziftomenib), which generated $9.1 million in net product revenue and captured a majority share of new patient starts in its class. The company also presented positive clinical data for ziftomenib in AML and for darlifarnib in solid tumors, reinforcing their potential across various cancer treatments. Kura Oncology reported $519.0 million in cash, cash equivalents, and short-term investments, projecting sufficient funds to advance its lead programs.
Earnings Flash (KURA) Kura Oncology, Inc. Reports Q2 Revenue $20.9M, vs. FactSet Est of $20.2M
Kura Oncology, Inc. (KURA) reported Q2 revenue of $20.9 million, surpassing FactSet's estimated $20.2 million. This earnings flash indicates a positive revenue surprise for the biotechnology and medical research company. The report also mentions other recent financial news, including a widened Q2 diluted loss and an adjusted price target by Wedbush to $38 from $36.
Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity
Kura Oncology announced the publication of a manuscript in Blood detailing the discovery and preclinical development of ziftomenib, a menin inhibitor approved by the FDA for relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). The publication highlights ziftomenib's differentiated binding profile, potent and selective inhibition, and activity against certain resistance-associated mutations. This research supports ziftomenib's potential as a foundational therapy across genetically defined acute leukemias and reinforces its advancement from an early discovery program to an approved medicine.
Kura Oncology publishes study highlighting ziftomenib's unique action and potential in treating acute leukemias.
Kura Oncology announced the publication of a study in the journal Blood detailing the discovery and preclinical development of ziftomenib, an FDA-approved menin inhibitor for relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). The study highlights ziftomenib's potent and selective inhibition of the menin-KMT2A interaction, its activity against resistance-associated mutations, and its effectiveness in multiple leukemia models. Kura Oncology continues clinical development to broaden ziftomenib's benefit to more patients with menin-dependent leukemias.
Kura Oncology publishes preclinical data on ziftomenib in Blood By Investing.com
Kura Oncology has published preclinical data in Blood journal detailing the discovery and development of ziftomenib, a menin inhibitor approved by the FDA in 2025 for adult patients with relapsed or refractory NPM1-mutated acute myeloid leukemia. The research highlights ziftomenib's efficacy across various leukemia models and its ability to retain activity against certain resistance-associated menin mutations. Kura Oncology is further studying ziftomenib across the AML treatment continuum.
Hennion & Walsh Asset Management Inc. Grows Stake in Kura Oncology, Inc. $KURA
Hennion & Walsh Asset Management Inc. significantly increased its stake in Kura Oncology (NASDAQ:KURA) by 69.7% in Q2, bringing its total holdings to 568,845 shares valued at $6.24 million. Despite reporting a quarterly loss that beat estimates, revenue fell short, and an insider recently sold a substantial number of shares. Analysts maintain a "Moderate Buy" rating for KURA with an average price target of $25.46.
Dimensional Fund Advisors LP Increases Holdings in Kura Oncology, Inc. $KURA
Dimensional Fund Advisors LP significantly increased its stake in Kura Oncology, Inc. by 32.3% in the first quarter, now holding 1.43 million shares valued at $11.6 million. Other institutions also grew their positions, while an insider sold shares. Analysts maintain a "Moderate Buy" rating with an average price target of $25.46 against the current price of $9.57, despite the company's unprofitability.
Kura Oncology, Inc. (KURA) Stock Price, News, Quote & History
This Yahoo Finance page provides comprehensive financial data for Kura Oncology, Inc. (KURA), including its current stock price, historical performance, key statistics, earnings trends, and analyst ratings. It also offers an overview of the company's biopharmaceutical operations, focusing on its cancer treatment drug development.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. announced that its Compensation Committee granted inducement awards consisting of nonstatutory stock options to purchase 104,500 shares of common stock to six new employees. These grants were made on August 3, 2026, under the Company’s 2023 Inducement Option Plan, as amended, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $9.19 per share and will vest over four years, subject to continued employment.
Six New Employees Receive Kura Oncology Options at $9.19
Kura Oncology (Nasdaq: KURA) has granted inducement awards of nonstatutory stock options to six new employees, totaling 104,500 shares. The options have an exercise price of $9.19 per share, matching the closing price on August 3, 2026, and will vest over four years. These awards comply with Nasdaq Listing Rule 5635(c)(4) as employment inducements.
Kura Oncology to Report Second Quarter Financial Results
Kura Oncology, Inc. announced it will report its second quarter 2026 financial results after market close on Wednesday, August 12, 2026. Management will host a webcast and conference call at 4:30 p.m. ET to discuss the results and provide a corporate update. The company is a biopharmaceutical firm focused on precision medicines for cancer treatment, with an FDA-approved drug, KOMZIFTI® (ziftomenib), for relapsed or refractory NPM1-mutated acute myeloid leukemia.
Cancer drugmaker Kura Oncology schedules Aug. 12 webcast
Kura Oncology (Nasdaq: KURA) will report its second quarter 2026 financial results after the close of U.S. financial markets on Wednesday, August 12, 2026. The company will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and provide a corporate update. Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer, including the FDA-approved KOMZIFTI (ziftomenib) for NPM1-mutated acute myeloid leukemia.
How Kura Oncology Inc. (KURA) Affects Rotational Strategy Timing
Kura Oncology Inc. (KURA) shows weak near and mid-term sentiment despite a positive long-term outlook, driven by an exceptional short setup. AI models have generated distinct trading strategies, including long, breakout, and short positions, each with specific entry, target, and stop-loss levels. The analysis highlights a 54.3:1 risk-reward short setup, targeting a 16.4% downside with only 0.3% risk.
How Kura Oncology Inc. (KURA) Affects Rotational Strategy Timing
This article analyzes Kura Oncology Inc. (KURA) for rotational strategy timing, highlighting weak near- and mid-term sentiment but a strong long-term outlook. It details specific trading strategies, including long, breakout, and short positions, with entry points, targets, and stop losses derived from AI models. The analysis also provides multi-timeframe signal strengths and support/resistance levels for KURA.
Kura Oncology Inc (KURA) Financial Health: Profitability & Balance Sheet Analysis
Kura Oncology Inc (KURA) has a current financial score of 6.02, indicating a weak financial status and low operating efficiency within the Biotechnology & Medical Research industry. Despite this, the company reported a year-over-year revenue increase of 29.47% and a net profit increase of 27.69% in its latest quarter. The analysis highlights areas like Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns, noting that relevant data for some of these metrics have not yet been disclosed by the company.
Kura Oncology Inc (KURA) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Kura Oncology Inc (KURA), highlighting its current earnings forecast score, analyst ratings, and price targets. The company ranks 146 out of 384 in the Biotechnology & Medical Research industry, with most analysts recommending a "Buy" for the stock. Key financial expectations for EPS and revenue are also detailed.
Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026
Kura Oncology announced encouraging and durable clinical activity results from its FIT-001 clinical trial for darlifarnib plus cabozantinib in cabozantinib-naïve clear cell renal cell carcinoma patients. The study showed objective response rates up to 50% and a median progression-free survival of 13 months, with a manageable safety profile. These findings support the continued development of the combination therapy and a global, randomized Phase 1b study is underway to determine the recommended Phase 3 dose.
Kura Oncology (NASDAQ: KURA) revises CEO and executive severance
Kura Oncology (NASDAQ: KURA) has revised the employment agreements for its CEO, CCO, and COO to update severance and change-of-control protections. These new terms define cash severance, COBRA coverage, equity vesting, and stock option exercise rights, differentiating based on whether a termination is linked to a "Corporate Transaction." The updated agreements aim to provide enhanced financial security to the executives in various termination scenarios, with full details to be made public in the upcoming Form 10-Q filing.
A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $28 to $40
This article provides a quick look at analyst ratings for Kura Oncology (KURA.US). Forecasts for the company's stock price range from $28 to $40. Investors are encouraged to consider these ratings as part of a broader investment strategy.
KURA Reiterates by Wedbush -- Price Target Maintained at $36
Wedbush has reiterated an "Outperform" rating for Kura Oncology (KURA) and maintained a price target of $36.00, signaling confidence despite the company's low GF Score™ of 28/100, which highlights profitability and growth challenges. Insider activity, marked by $1.0 million in net selling and no buying over the past three months, suggests caution is warranted for potential investors. Kura Oncology is a biopharmaceutical company focused on developing targeted cancer therapies, currently valued at approximately $901.5 million.
Kura Oncology Reports 50% Response Rate in RCC Combination Study
Kura Oncology announced promising updated results from its Phase 1 FIT-001 trial, showing a 50% objective response rate in cabozantinib-naive clear cell RCC patients treated with darlifarnib and cabozantinib. The combination therapy demonstrated a manageable safety profile, with neutropenia being the most notable adverse event. Kura plans to continue development, with further data expected in late 2027, and sees potential for darlifarnib in later-line and broader combinations for advanced RCC.
KURA|Kura Oncology Inc|Price:10.150|Chg%:-0.240
Kura Oncology Inc (KURA) has a relatively weak fundamental but high growth potential, with its valuation considered fairly valued within the Biotechnology & Medical Research industry. The company has high institutional ownership and analysts generally rate it as a "Buy" with a significant upside space. Kura Oncology is a clinical-stage biopharmaceutical company focused on precision medicine for cancer treatment, with products like Ziftomenib, Tipifarnib, and KO-2806 in its pipeline.
H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $40
H.C. Wainwright has reiterated its Buy rating for Kura Oncology (KURA.US), maintaining a target price of $40. This suggests a continued positive outlook on the company's stock performance.
Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026
Kura Oncology announced durable clinical activity results from its FIT-001 clinical trial, demonstrating encouraging outcomes for darlifarnib plus cabozantinib in cabozantinib-naïve advanced clear cell renal cell carcinoma patients. The study showed objective response rates up to 50% and a median progression-free survival of 13 months, with a manageable safety profile. These findings support continued development and a planned registrational study for the combination therapy.
Kura Oncology Reports Encouraging Phase 1a Data for Darlifarnib Plus Cabozantinib in Advanced Clear Cell Renal Cell Carcinoma
Kura Oncology announced positive Phase 1a results from its FIT-001 clinical trial for darlifarnib plus cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC). The combination therapy demonstrated response rates up to 50% and a median progression-free survival of 13 months, along with a manageable safety profile. A randomized Phase 1b study is underway to further optimize dosing and inform a potential Phase 3 registrational study.
Kura Oncology reports up to 50% response rate for darlifarnib-cabozantinib combo in Phase 1a kidney cancer trial
Kura Oncology announced positive Phase 1a results for its darlifarnib-cabozantinib combination therapy in advanced clear cell renal cell carcinoma, showing up to a 50% response rate and durable tumor shrinkage. The company is currently enrolling for a randomized Phase 1b study to determine the optimal Phase 3 dose, with plans for a registrational study in 2028. This combination aims to provide a new treatment option following immunotherapy-based therapies.
Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026
Kura Oncology announced encouraging Phase 1a results for darlifarnib plus cabozantinib in cabozantinib-naïve clear cell renal cell carcinoma (ccRCC) patients, showing high response rates and a median progression-free survival of 13 months. The combination demonstrated a manageable safety profile and durable clinical benefit, supporting its potential to enhance VEGFR-targeted therapies. A global, randomized Phase 1b study is currently underway to determine the recommended Phase 3 dose for a planned registrational study in 2028.
Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026
Kura Oncology announced updated Phase 1a results from its FIT-001 trial, showing that the combination of darlifarnib plus cabozantinib achieved objective response rates of 33% to 50% and a median progression-free survival of 13 months in patients with advanced clear cell renal cell carcinoma. The data indicates durable clinical activity and a manageable safety profile. Kura Oncology plans for a randomized Phase 1b study to determine the recommended Phase 3 dose, with a registrational study targeted for 2028.
Why Did KURA Stock Jump 13% In Pre-Market Today?
Kura Oncology (KURA) shares surged over 13% in pre-market trading after the biotech firm reported encouraging early data from its ongoing trial for advanced kidney cancer. The trial for its investigational therapy, Darlifarnib, in combination with Cabozantinib, showed a 44% objective response rate and a 94% disease control rate, with tumor shrinkage in 75% of patients. This positive initial data has led to an "extremely bullish" retail sentiment despite a small sample size.
